Smolen J S.Aletaha D,Koeller M,et al.New therapies for treatment of rheumatoid arthritis[J].Lancet,2007,370(9802):1861-1874.New therapies for treatment of rheumatoid arthritis. JS Smolen,D Aletaha,M Koeller,MH Weisman,P Emery. The Lancet . 2007...
Rheumatoid arthritis is a painful inflammatory condition affecting the joints and tendons, which is typically characterized by periods of increased disease activity. Prof. Dr. Gerd-Rüdiger Burmester, head of Charité's Medical Department, Division of Rheumatology and Clinical Immunology, conducted a stud...
I have studied and treated ankylosing spondylitis (AS) for almost 10 years. It’s a form of axial spondyloarthritis (axSpA). That’s a type of inflammatory arthritis that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis. In its early sta...
Harnessing the power of the human immune system is steadily gaining recognition for its importance in the treatment of cancer.13BsAbs can simultaneously bind to two different antigens.14The most widely used BsAb is a bispecific T cell engager (BiTE), with one arm targeting CD3 on T cells and...
that signal your cells to make more inflammation. One study found that people who took a JAK inhibitor for just over 3 months were twice as likely to have a strong response as those who took a placebo, or fake pill. Two drugs, tofacitinib and upadacitinib, are in clinical trials. We ...
Citation97 For the treatment of rheumatoid arthritis (RA), the potential role of the gut microbiota patterns in the prediction of methotrexate efficacy were investigated. RA patients displayed two different enterotypes: RA E1, comprising predominantly Prevotella, and RA E2, comprising predominantly ...
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064–3076 (2010). This study reports the first successful use of an inflammasome pathway inhibitor in human disease, showing that ...
Infliximab, a chimeric monoclonal antibody, is an anti-treatment for . In the past there was a sizeable group of people who had exhausted disease-modifying (DMARDs) and were left largely untreated. This has been revolutionized by treatments such as infliximab which have been shown to be effecti...
“We are very pleased to have this IND under review by the FDA,” said Dr., President & Chief Executive Officer of Aclaris. “We look forward to beginning the development of ATI-450 as a potential treatment for rheumatoid arthritis and other potential indications driven by TNF...
Treatment of ulcerative colitis with an engineered human anti-TNF-α antibody CDP571 [abstract]. Gastroenterology 1996; 110: A905 Article Google Scholar Baert F, D’Haens G, Geboes K, et al. TNF-α antibody therapy causes a fast and dramatic decrease of histological colonic inflammation in ...